5.0E-4 (9.091%)
ASX:Live
Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Valuation
Value
Consensus
Momentum
Price
Neutral
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
N/A
Telephone
N/A
Address
Description
Anatara Lifesciences Ltd. engages in the development of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. It also develops and commercializes Detach, a non-antibiotic therapy that prevents and treats diarrhea in piglets. The company was founded by Tracey Mynott on July 15, 2010 and is headquartered in Adelaide, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.07
Trade Value (12mth)
AU$1,863.00
1 week
0%
1 month
0%
YTD
-88%
1 year
-84.62%
All time high
1.66
EPS 3 yr Growth
-66.40%
EBITDA Margin
N/A
Operating Cashflow
-$1m
Free Cash Flow Return
-109.00%
ROIC
-126.80%
Interest Coverage
N/A
Quick Ratio
5.50
Shares on Issue (Fully Dilluted)
196m
HALO Sector
Healthcare
Next Company Report Date
20-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
| Date | Announcements |
|---|---|
|
01 May 25 |
Funding Advance on R&D Refund
×
Funding Advance on R&D Refund |
|
30 April 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
|
17 April 25 |
Phase II GaRP-IBS Trial Headline Analysis of Results
×
Phase II GaRP-IBS Trial Headline Analysis of Results |
|
10 March 25 |
Phase II GaRP-IBS Trial & Anti-Obesity Project Updates
×
Phase II GaRP-IBS Trial & Anti-Obesity Project Updates |
|
07 March 25 |
Initial Director's Interest Notice
×
Initial Director's Interest Notice |
|
07 March 25 |
Final Director's Interest Notice
×
Final Director's Interest Notice |
|
06 March 25 |
Trading Halt
×
Trading Halt |
|
28 February 25 |
Board Changes
×
Board Changes |
|
25 February 25 |
Appendix 4D & Half Year Report 31 December 2024
×
Appendix 4D & Half Year Report 31 December 2024 |
|
20 February 25 |
Phase II GaRP-IBS Trial & Anti-Obesity Project Updates
×
Phase II GaRP-IBS Trial & Anti-Obesity Project Updates |
|
28 January 25 |
Australian Patent Granted for GaRP Product
×
Australian Patent Granted for GaRP Product |
|
15 January 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
|
24 December 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
|
24 December 24 |
Notification regarding unquoted securities - ANR
×
Notification regarding unquoted securities - ANR |
|
23 December 24 |
Application for quotation of securities - ANR
×
Application for quotation of securities - ANR |
|
23 December 24 |
Addendum to Company Presentation released on 2 December 2024
×
Addendum to Company Presentation released on 2 December 2024 |
|
20 December 24 |
Share Purchase Plan Results
×
Share Purchase Plan Results |
|
13 December 24 |
GaRP-IBS Clinical Trial Update
×
GaRP-IBS Clinical Trial Update |
|
04 December 24 |
GaRP-IBS Clinical Trial Update
×
GaRP-IBS Clinical Trial Update |
|
02 December 24 |
Investor Presentation
×
Investor Presentation |
|
02 December 24 |
Webinar and Q&A
×
Webinar and Q&A |
|
29 November 24 |
Company Secretary Appointment/Resignation
×
Company Secretary Appointment/Resignation |
|
27 November 24 |
Cleansing Notice
×
Cleansing Notice |
|
27 November 24 |
Share Purchase Plan Offer Booklet
×
Share Purchase Plan Offer Booklet |
|
27 November 24 |
Share Purchase Plan Shareholder Letter
×
Share Purchase Plan Shareholder Letter |
Load More
Load Less
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
.svg)
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.
